These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 30803931)
1. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931 [TBL] [Abstract][Full Text] [Related]
2. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911 [TBL] [Abstract][Full Text] [Related]
3. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Chang L; Hu Z; Zhou Z; Zhang H Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527 [TBL] [Abstract][Full Text] [Related]
4. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1. Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082 [TBL] [Abstract][Full Text] [Related]
5. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway. Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1. Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245 [TBL] [Abstract][Full Text] [Related]
7. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC. Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683 [TBL] [Abstract][Full Text] [Related]
8. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. Li D; Wang X; Yang M; Kan Q; Duan Z Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483 [TBL] [Abstract][Full Text] [Related]
9. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer. Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563 [TBL] [Abstract][Full Text] [Related]
10. Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation. Wang Z; Tong D; Han C; Zhao Z; Wang X; Jiang T; Li Q; Liu S; Chen L; Chen Y; Li A; Huang C EBioMedicine; 2019 Mar; 41():357-369. PubMed ID: 30797711 [TBL] [Abstract][Full Text] [Related]
11. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Zhao Q; Liu Y; Wang T; Yang Y; Ni H; Liu H; Guo Q; Xi T; Zheng L Eur J Pharmacol; 2020 Oct; 884():173359. PubMed ID: 32738343 [TBL] [Abstract][Full Text] [Related]
12. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells. Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199 [TBL] [Abstract][Full Text] [Related]
13. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499 [TBL] [Abstract][Full Text] [Related]
14. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Ghebeh H; Lehe C; Barhoush E; Al-Romaih K; Tulbah A; Al-Alwan M; Hendrayani SF; Manogaran P; Alaiya A; Al-Tweigeri T; Aboussekhra A; Dermime S Breast Cancer Res; 2010; 12(4):R48. PubMed ID: 20626886 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1. Zhu J; Zhang R; Yang D; Li J; Yan X; Jin K; Li W; Liu X; Zhao J; Shang W; Yu T Cell Physiol Biochem; 2018; 51(1):113-128. PubMed ID: 30439718 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072 [TBL] [Abstract][Full Text] [Related]
19. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway. Wu H; Li J; Guo E; Luo S; Wang G Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800 [TBL] [Abstract][Full Text] [Related]
20. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis. Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322 [No Abstract] [Full Text] [Related] [Next] [New Search]